GlassScriptPhysician profile
Pamela L Mcmaster
NPI 1497130272
$10,373.73
in general payments reported to CMS, 2019-2025
54 companies · $16.32 in 2025
The $16.32 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,608 · 2022: $4,166 · 2023: $2,566 · 2024: $17.96 · 2025: $16.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,592 · Education: $8.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,591.67 |
| Education | $8.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,744.88 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $727.80 | 2021-2023 | |
| Livanova USA, INC. | $674.49 | 2021-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $488.73 | 2021-2023 | Briviact |
| Emd Serono, INC. | $481.98 | 2021-2023 | Mavenclad |
| Sk Life Science, INC. | $477.65 | 2021-2023 | Xcopri |
| Biogen, INC. | $425.68 | 2021-2023 | Vumerity, Tysabri |
| Lilly USA, LLC | $408.27 | 2021-2023 | Emgality, Reyvow, Amyvid |
| Acadia Pharmaceuticals INC | $386.09 | 2021-2023 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $343.62 | 2021-2023 | Austedo Xr |
| Amgen INC. | $322.23 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $283.49 | 2021-2023 | |
| Neurocrine Biosciences, INC. | $251.93 | 2021-2023 | Ingrezza, Ongentys |
| Eisai INC. | $204.42 | 2021-2022 | |
| Celgene Corporation | $204.11 | 2021-2024 | Zeposia |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Mcmaster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.